Brief: Aquestive Therapeutics Announces Pivotal Study For Anaphylm
14/03/2024 21:42
March 14 (Reuters) - Aquestive Therapeutics Inc
AQST.O :
* AQUESTIVE THERAPEUTICS ANNOUNCES PIVOTAL STUDY FOR
ANAPHYLM™
(EPINEPHRINE) SUBLINGUAL FILM SUCCESSFULLY MEETS PRIMARY AND
SECONDARY ENDPOINTS AND PROVIDES CLINICAL DEVELOPMENT UPDATE
FOLLOWING FDA MEETING
* AQUESTIVE THERAPEUTICS INC - ANAPHYLM IS WELL-TOLERATED
WITH NO
SERIOUS ADVERSE EVENTS
* AQUESTIVE THERAPEUTICS INC - ANAPHYLM TIME TO MAXIMUM
CONCENTRATION (TMAX) IS CONSISTENTLY FASTER THAN AUTOINJECTORS
* AQUESTIVE THERAPEUTICS INC: COMPANY REAFFIRMS GOAL OF
FILING NDA
BEFORE END OF 2024
* AQUESTIVE THERAPEUTICS INC - RECEIVES POSITIVE TYPE C
MEETING
FEEDBACK FROM U.S. FDA REGARDING CLINICAL DEVELOPMENT OF
ANAPHYLM
* AQUESTIVE THERAPEUTICS INC - ANAPHYLM EXPOSURE LEVELS
(AUC) ARE
COMPARABLE TO AUTOINJECTORS FOR 30 MINUTES AFTER DOSING
Source text for Eikon: ID:nGNX2FdQcP
Further company coverage: AQST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million